Abound Wealth Management’s Corcept Therapeutics CORT Stock Holding History

Abound Wealth Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$348	Hold	4	–	–	﹤0.01%	1007
2026 Q1	$162	Sell	4 -1	-20%	-$37	﹤0.01%	1301
2025 Q4	$174	Hold	5	–	–	﹤0.01%	1229
2025 Q3	$416	Hold	5	–	–	﹤0.01%	948
2025 Q2	$367	Sell	5 -1	-17%	-$73	﹤0.01%	892
2025 Q1	$686	Sell	6 -2	-25%	-$122	﹤0.01%	788
2024 Q4	$404	Hold	8	–	–	﹤0.01%	827
2024 Q3	$371	Sell	8 -4	-33%	-$142	﹤0.01%	927
2024 Q2	$390	Hold	12	–	–	﹤0.01%	902
2024 Q1	$303	Hold	12	–	–	﹤0.01%	1128
2023 Q4	$390	Hold	12	–	–	﹤0.01%	1034
2023 Q3	$327	Hold	12	–	–	﹤0.01%	984
2023 Q2	$267	Buy	+12	New	+$276	﹤0.01%	1102

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Abound Wealth Management's CORT Position: Q2 2026 in Review

Abound Wealth Management held its Corcept Therapeutics (CORT) position steady in Q2 2026 at 4 shares worth $348. The position accounts for ﹤0.01% of the portfolio, ranked #1007.

Abound Wealth Management first reported a position in CORT in Q2 2023 and has held it in 13 quarters since. The position peaked at $686 in Q1 2025. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

Abound Wealth Management held 4 shares of Corcept Therapeutics worth $348 as of Q2 2026.
Abound Wealth Management left its Corcept Therapeutics share count unchanged in Q2 2026.
Corcept Therapeutics made up ﹤0.01% of Abound Wealth Management's portfolio in Q2 2026, its #1007 holding.
Abound Wealth Management first reported a position in Corcept Therapeutics in Q2 2023 and has held it in 13 quarters since.
Abound Wealth Management's Corcept Therapeutics position peaked at $686 in Q1 2025.
422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Abound Wealth Management's 13F filing for Q2 2026, filed 10 Jul 2026.